Find disease awareness content and relevant supporting materials

NICE (National Institute for Health and Care Excellence (UK)recommended Trodelvy (also called sacituzumab govitecan and made by Gilead Sciences) for treating locally advanced or metastatic triple negative breast cancer which cannot be removed surgically.

In the fourth part of our four-part series detailing targeted breast cancer therapies, we focus on the most aggressive and difficult to treat triple negative breast cancer subtype.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda (pembrolizumab) from Merck Sharp & Dohme for triple negative breast cancer.

Merck Inc announced that the European Commission (EC) has approved Keytruda (pembrolizumab), in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] of at least 10) and who have not received prior chemotherapy for metastatic disease.

Gilead Sciences, Inc. and Immunomedics announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash.

Gilead Sciences, Inc. announced that Health Canada has approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior therapies, at least one of them for metastatic disease.

Everest Medicines a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that China's National Medical Products Administration (NMPA) has approved Trodelvy (sacituzumab govitecan or SG) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Merck Inc., announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Keytruda, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) in adults whose tumors express PD-L1 (Combined Positive Score [CPS] ?10) and who have not received prior chemotherapy for metastatic disease.

The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending Tecentriq (atezolizumab), from Roche, with chemotherapy drug Abraxane (nab-paclitaxel), for treating patients with metastatic triple negative breast cancer.